Gurgoglione Filippo Luca, Gattuso Dario, Greco Antonio, Benatti Giorgio, Niccoli Giampaolo, Cortese Bernardo
Division of Cardiology, University of Parma, Parma University Hospital, Parma, Italy; Division of Cardiology, Parma University Hospital, Parma, Italy; DCB Academy, Milano, Italy.
Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy.
Am J Cardiol. 2025 Mar 15;239:68-74. doi: 10.1016/j.amjcard.2024.12.015. Epub 2024 Dec 16.
Percutaneous coronary intervention (PCI) with drug-coated balloon (DCB) has been expanding progressively in recent years. Convincing evidence demonstrated the ability of some DCB to promote positive vessel remodeling, with potential clinical benefits at follow-up. When PCI with DCB results in suboptimal angiographic results (residual stenosis >30% or type C to F dissection), bailout stenting (BS) implantation is recommended to mitigate the risk of abrupt vessel occlusion or restenosis. However, clinical studies focusing on BS during PCI with DCB are scarce. This study aimed to compare the 2-year clinical outcomes of patients requiring BS with those who underwent sirolimus-coated balloon (SCB)-only PCI and investigate clinical and angiographic predictors of BS. We conducted a post hoc analysis of the prospective, multicenter, thE All-comers Sirolimus-coaTed BallOon eURopeaN rEgistry (EASTBOURNE) study. The overall cohort was stratified into 2 study groups: patients requiring BS versus those who underwent SCB-only PCI. The primary end point was target lesion revascularization (TLR) at the 24-month follow-up. Propensity score matching was used to balance clinical and procedural characteristics between the 2 study groups. The study population included 2,084 patients for a total of 2,318 treated lesions. Of them, 181 (7.8%) required BS for suboptimal results during PCI with SCB. Coronary lesions requiring BS were more frequently de novo stenoses (p = 0.016), longer (p = 0.012), and had a smaller median reference vessel diameter (p <0.001). At 24 months, TLR occurred in 133 (6.4%) patients. The 2 study groups experienced a similar rate of TLR in the unmatched cohort (6.3% in the SCB-only group vs 7.3% in the BS group, p = 0.683) and after propensity score matching analysis (4.2% in the SCB-only group vs 8.5% in the BS group, p = 0.223). These results were consistent when considering subpopulations with de novo lesions, in-stent restenosis, and large and small vessel disease. Revascularization of de novo lesions and smoking habit were independent positive predictors of BS, whereas the SCB inflation time was an independent negative predictor of BS by multivariable logistic analysis in the overall population. In contrast, we did not record any case of vessel thrombosis during follow-up. In conclusion, BS was associated with similar 2-year outcomes compared with SCB-only PCI and, thus, appear to be a safe bailout strategy for suboptimal angiographic results after DCB angioplasty.
近年来,药物涂层球囊(DCB)经皮冠状动脉介入治疗(PCI)的应用逐渐增多。有力证据表明,部分DCB具有促进血管正向重塑的能力,随访中具有潜在临床获益。当DCB PCI术后血管造影结果欠佳(残余狭窄>30%或C至F型夹层)时,建议植入补救支架(BS)以降低血管急性闭塞或再狭窄风险。然而,针对DCB PCI术中BS的临床研究较少。本研究旨在比较需要BS的患者与仅接受西罗莫司涂层球囊(SCB)PCI患者的2年临床结局,并探讨BS的临床和血管造影预测因素。我们对前瞻性、多中心、全入组西罗莫司涂层球囊欧洲注册研究(EASTBOURNE)进行了事后分析。整个队列分为2个研究组:需要BS的患者与仅接受SCB PCI的患者。主要终点为24个月随访时的靶病变血运重建(TLR)。采用倾向评分匹配法平衡2个研究组之间的临床和手术特征。研究人群包括2084例患者,共治疗2318处病变。其中,181例(7.8%)在SCB PCI术中因结果欠佳需要BS。需要BS的冠状动脉病变更多为初发狭窄(p = 0.016)、更长(p = 0.012),且中位参考血管直径更小(p <0.001)。24个月时,133例(6.4%)患者发生TLR。在未匹配队列中,2个研究组的TLR发生率相似(仅SCB组为6.3%,BS组为7.3%,p = 0.683),倾向评分匹配分析后也相似(仅SCB组为4.2%,BS组为8.5%,p = 0.223)。在考虑初发病变、支架内再狭窄以及大血管和小血管疾病亚组时,结果一致。初发病变血运重建和吸烟习惯是BS的独立阳性预测因素,而在总体人群中,多变量逻辑分析显示SCB充盈时间是BS的独立阴性预测因素。相比之下,随访期间未记录到任何血管血栓形成病例。总之,与仅接受SCB PCI相比,BS的2年结局相似,因此,对于DCB血管成形术后血管造影结果欠佳的情况,BS似乎是一种安全的补救策略。